Compare Elanco Animal Health Incorporated Common Stock (ELAN) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elanco Animal Health Incorporated Common Stock vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.55 (market cap $11.20B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B). The key difference: Elanco Animal Health Incorporated Common Stock is far larger — about 8.2× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Elanco Animal Health Incorporated Common Stock is trading nearer its 52-week high, Americas Gold and Silver Corporation Common Shares no par value nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| ELAN | USAS | |
|---|---|---|
Market Cap | $11.20B | $1.36B |
Volume | 3,345,224 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $26.84 | $10.03 |
52-Week Low | $19.80 | $3.59 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $1.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elanco Animal Health Incorporated Common Stock
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
